Sugi Predict

Sugi Predict / Compounds / 5-Fluoroisatin

5-Fluoroisatin

5-Fluoroisatin

SCHEMBL183575

O=C1Nc2ccc(F)cc2C1=O

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 6/20 0.61
▸ MAOA P21397 5/20 0.61
▸ TGM2 P21980 6/20 0.60
▸ CES1 P23141 4/20 0.60
▸ LRRK2 Q5S007 2/20 0.55
▸ CA1 P00915 2/20 0.55
▸ CA2 P00918 2/20 0.55
▸ CA12 O43570 1/20 0.55
▸ CA9 Q16790 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ CASP3 P42574 2/20 0.53
▸ CAPN9 O14815 1/20 0.53
▸ PDE3B Q13370 1/20 0.51
▸ PDE3A Q14432 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
5-Fluoroisatin SCHEMBL28512324 0.98 MAOB (0.59) MAOBMAOATGM2CES1LRRK2
5-Fluoroisatin SCHEMBL29155951 0.96 MAOB (0.58) MAOBMAOATGM2CES1LRRK2
5-Fluoroisatin SCHEMBL7829877 0.91 MAOB (0.69) MAOBMAOATGM2CES1LRRK2
5-Fluoroisatin SCHEMBL11132105 0.89 CES1 (0.80) MAOBMAOATGM2CES1LRRK2
5-Fluoroisatin SCHEMBL8708925 0.88 MAOB (0.51) MAOBMAOATGM2CES1LRRK2
SCHEMBL17993494 0.87 LRRK2 (0.54) MAOBMAOALRRK2CA1CA2
SCHEMBL29906173 0.85 MAOB (0.72) MAOBMAOATGM2CES1CA1
SCHEMBL2788548 0.85 MAOB (0.72) MAOBMAOATGM2CES1CA1
SCHEMBL2307937 0.83 CES1 (0.60) MAOBMAOATGM2CES1
SCHEMBL21708143 0.83 MAOB (0.45) MAOBMAOATGM2CES1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 998 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119684105-A N-phenyl isatin-mediated ketone-carboxylic acid conversion reaction method 贵州医科大学 2025-03-25 — — CN claimed
CN-119552328-A Substituted isatin aromatic hydrocarbon copolymer, preparation method and polymer anion exchange membrane 北京志氢科技有限公司 2025-03-04 — — CN claimed
CN-119409630-A Asymmetric polyfluoro-substituted 2,4' -biquinoline-4-amide derivative and preparation method and application thereof 郑州工业应用技术学院 2025-02-11 — — CN claimed
CN-118852031-A 2, 3-Disubstituted quinazolinone compound and preparation method thereof 赣南师范大学 2024-10-29 — — CN claimed
CN-117586485-A Sulfonated hydrocarbon polymer containing protecting group, synthesis method and application thereof in low-temperature proton exchange membrane fuel cell 中国科学院山西煤炭化学研究所 2024-02-23 — — CN claimed
CN-111187233-B Polysubstituted benzothiazole and derivative and synthesis method thereof 湘潭大学 2023-05-30 — — CN claimed
CN-113912609-A Preparation method of natural alkaloid tryptanthrin and derivative thereof 江苏大学 2022-01-11 — — CN claimed
CN-110183454-B Tryptanthrin containing 1,2, 3-triazole and preparation method and application thereof 同济大学 2022-01-07 — — CN claimed
CN-110041335-B Method for improving water solubility of tryptanthrin, tryptanthrin derivative, preparation method and application thereof 同济大学 2022-01-07 — — CN claimed
CN-110437233-B Tryptanthrin derivative containing olefine acid and preparation method and application thereof 同济大学 2022-01-07 — — CN claimed
JP-2011526615-A — — 2011-10-13 — — JP claimed
CN-102137842-A Preparation of 3-pyrrole substituted 2-indolinone derivatives GENERICS UK LTD 2011-07-27 — — CN claimed
EP-2318364-A2 PREPARATION OF 3-PYRROLE SUBSTITUTED 2-INDOLINONE DERIVATIVES Generics [UK] Limited (GB) 2011-05-11 — — EP claimed
EP-2313396-A1 PROCESS FOR THE PREPARATION OF HIGH PURITY SUNITINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALT Natco Pharma Limited (IN) 2011-04-27 — — EP claimed
US-20110092717-A1 PROCESS FOR THE PREPARATION OF HIGH PURITY SUNITINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALT NATCO PHARMA LIMITED (IN) 2011-04-21 — — US claimed
WO-2010001167-A2 NOVEL PROCESS GENERICS [UK] LIMITED (GB) 2010-01-07 — — WO claimed
WO-2009157011-A1 PROCESS FOR THE PREPARATION OF HIGH PURITY SUNITINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALT NATCO PHARMA LIMITED (IN) 2009-12-30 — — WO claimed
US-6114540-A COMBINATORIAL LIBRARIES ARQULE, INC. (US) 2000-09-05 — — US claimed
EP-0599732-B1 Derivatives of 1-phenylbicyclo-2,2,2-octane, their preparation process and pharmaceutical compositions containing them ADIR (FR) 1997-03-12 — — EP claimed
EP-0599732-A1 Derivatives of 1-phenylbicyclo-2,2,2-octane, their preparation process and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1994-06-01 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092717-A1 PROCESS FOR THE PREPARATION OF HIGH PURITY SUNITINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALT MET, RCC2, MDH2 MAOB 2507/4885MAOA 2553/4885TGM2 3612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.